Probi[®] Sensia - New probiotic concept within cognitive health
Cognitive function, Mood, Sleep and Stress – keywords that are addressed in the new clinically supported probiotic solution, Probi® Sensia to be launched by Probi ® at SupplySide West in October 2023.
Mental health supplements have emerged as the fastest-growing benefit within the global dietary supplements market. Over five years (2017-2021), we’ve seen a 30 percent growth in probiotic launches positioned within Brain-Mood Health1, showing how psychobiotics is a fast-rising niche2.
Within the scientific community, the connection between gut and neurocognitive functions has been a major research topic during the last couple of years. Stress, anxiety and depression-like symptoms were the first to be addressed, but today there are more and more research being carried out in healthy individuals, as the focus has shifted towards finding solutions to the “everyday” issues that many of us struggle with – poor sleep quality, moody-behavior and issues with cognitive functions such as memory and focus.
Probi® Sensia is a new probiotic concept by Probi® based on clinical and scientific data that supports improved cognition by boosting learning and working memory as well as improved mood and sleep. These cognitive functions are important in enhancing people´s overall mental health. The new probiotic solution will be available to meet diverse consumer needs, supported by global health-related claims and customizable with local support. Furthermore, it can be combined with selected vitamins, minerals or other ingredients, and is ideal for dietary supplement formats like capsules, stick packs and functional foods such as beverages and powder products.
Probi ® Sensia is based on the well-documented probiotic strain Lactiplantibacillus plantarum HEAL9 (HEAL9™). Three clinical studies and totally five scientific articles have repeatably showed that intake of HEAL9™ affects the so-called gut-brain axis in a positive way. The clinical endpoints include decreased cortisol and stress-induced inflammation in chronically stressed but otherwise healthy students, as well as decreased symptoms of depression and anxiety. In the latest publication healthy individuals with moderate stress were evaluated. Improved memory and cognitive function, improved sleep quality and decreased daytime dysfunction, as well as improved mood was found after intake of the HEAL9™ strain.
“We are proud to launch our new concept Probi ® Sensia, based on a strong clinically proven effect, which optimizes and maintains important cognitive functions such as memory as well as mood, sleep and stress. With Probi ® Sensia we now offer a wide-ranging solution to help our customers to meet diverse consumer needs from a health-related perspective with a broad usage from dietary supplements to functional foods and beverages. We are looking forward to meet up at SupplySide West to show the advantages of our latest innovation." says Anita Johansen, CEO of Probi.
The latest study “Intake of Lactiplantibacillus plantarum HEAL9 Improves Cognition in Moderately Stressed Subjects: A Randomized Controlled Study was recently published in Nutrients (2023) 15 (15), 3466, and can be found here: LINK
1Innova Market Insight 2022
2Further insights: “The gut-brain axis: Psychobiotic opportunity in 25 countries” (March 2022)
For further information, please contact:
Anita Johansen, CEO, Probi, Phone: +46 46 286 89 48, E-mail: [email protected]
ABOUT PROBI
Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for
supplements and functional food. We are experts at managing stable, live bacteria from R&D through every
stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics
available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Probi had sales of SEK 618 m in 2022. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,700 shareholders on December 31, 2022.
